Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- BOLD
- Price
- 1.27
- Stock movement up
- +0.03 (2.42%)
- Company name
- Boundless Bio, Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 28.43M
- Ent value
- 72.00M
- Price/Sales
- 26.92
- Price/Book
- 0.26
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 2.54%
- 1 year return (CAGR)
- -50.58%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BOLD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 26.92 |
| Price to Book | 0.26 |
| EV to Sales | 68.18 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 22.39M |
| EPS (TTM) | -2.76 |
| FCF per share (TTM) | -2.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.06M |
| Gross profit (TTM) | -416.00K |
| Operating income (TTM) | -67.83M |
| Net income (TTM) | -61.76M |
| EPS (TTM) | -2.76 |
| EPS (1y forward) | -2.10 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -39.39% |
| Operating margin (TTM) | -6423.11% |
| Profit margin (TTM) | -5848.48% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 14.98M |
| Net receivables | 0.00 |
| Total current assets | 120.16M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 52.63M |
| Total assets | 168.72M |
| Accounts payable | 1.14M |
| Short/Current long term debt | 49.76M |
| Total current liabilities | 11.85M |
| Total liabilities | 58.55M |
| Shareholder's equity | 110.17M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -52.12M |
| Capital expenditures (TTM) | 588.00K |
| Free cash flow (TTM) | -52.70M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -56.06% |
| Return on Assets | -36.60% |
| Return on Invested Capital | -54.55% |
| Cash Return on Invested Capital | -46.55% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.25 |
| Daily high | 1.31 |
| Daily low | 1.25 |
| Daily Volume | 123K |
| All-time high | 13.62 |
| 1y analyst estimate | 3.00 |
| Beta | - |
| EPS (TTM) | -2.76 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| BOLD | S&P500 | |
| Current price drop from All-time high | -90.68% | -0.89% |
| Highest price drop | -92.58% | -19.00% |
| Date of highest drop | 30 Jun 2025 | 8 Apr 2025 |
| Avg drop from high | -87.56% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
28.43M
Marketcap category
Small-cap
Description
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. In addition, the company offers ECHO, an ecDNA harboring oncogenes diagnostic test to detect ecDNA in patient tumor specimens; and Spyglass platform, a platform used to identify druggable targets in oncogene amplified cancers. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Employees
64
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner